Literature DB >> 7207741

Surgical versus nonsurgical management of metastatic melanoma of the brain.

D A Fell, M E Leavens, C M McBride.   

Abstract

A retrospective analysis of 80 patients with cerebral metastases from melanoma revealed that 42 patients in whom the metastases were excised experienced a median survival of 5 months, in comparison with a 6-week median survival for 38 patients who were not operated upon. The same survival figures applied when comparing only patients with known Stage 4 disease at the time of diagnosis of the brain metastasis. The surgical mortality rate was 9.5% for the entire series and 5.4% for the 37 patients treated surgically since 1960.

Entities:  

Mesh:

Year:  1980        PMID: 7207741     DOI: 10.1227/00006123-198009000-00006

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  6 in total

1.  Surgery as palliative treatment for distant metastases of melanoma.

Authors:  I L Wornom; J W Smith; S J Soong; R McElvein; M M Urist; C M Balch
Journal:  Ann Surg       Date:  1986-08       Impact factor: 12.969

Review 2.  Outcomes After Curative Metastasectomy for Patients with Malignant Melanoma: A Systematic Review and Meta-analysis.

Authors:  Durgesh Wankhede; Sandeep Grover
Journal:  Ann Surg Oncol       Date:  2022-02-06       Impact factor: 5.344

3.  Cranial irradiation after surgical excision of brain metastases in melanoma patients.

Authors:  J M Skibber; S J Soong; L Austin; C M Balch; R E Sawaya
Journal:  Ann Surg Oncol       Date:  1996-03       Impact factor: 5.344

Review 4.  Surgical treatment of metastatic brain tumors.

Authors:  R Sawaya; B L Ligon; A K Bindal; R K Bindal; K R Hess
Journal:  J Neurooncol       Date:  1996-03       Impact factor: 4.130

5.  Brain metastasis from melanoma.

Authors:  T N Byrne; T L Cascino; J B Posner
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

Review 6.  Management of metastatic brain tumors.

Authors:  R Sawaya; B L Ligon; R K Bindal
Journal:  Ann Surg Oncol       Date:  1994-03       Impact factor: 5.344

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.